ArticleAsian Pacific journal of cancer prevention : APJCP2026
Gene Expression of MicroRNA-205, FGF2 and CARMA3 in Colorectal Cancer in Iraqi Patients.
Article in Asian Pacific journal of cancer prevention : APJCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) is a growing global health concern. This study focuses on evaluating the gene expression of FGF2, CARMA3, and MicroRNA205 (miR205) as potential blood-based biomarkers for early CRC diagnosis by distinguishing patients from healthy controls. MATERIALS AND
methodsBlood samples from 80 colorectal cancer (CRC) patients and 40 healthy controls were analyzed using qRT- PCR to measure target gene expression. ROC curve analysis was performed to evaluate diagnostic accuracy, including sensitivity, specificity, and Area Under the Curve (AUC) values.
resultsMicroRNA-205 revealed downregulation in CRC patients, with an AUC of 0.7, sensitivity of 91%, and specificity of 58%. AUC values for Fibroblast Growth Factor 2 (FGF2) and Caspase Recruitment Domain Family Member 3 (CARMA3) were 0.74 and 0.77, respectively, indicating differential expression. All markers displayed modest specificity, but CARMA3 showed the highest diagnostic accuracy with 95% sensitivity. Gene expression fold change for miR-205 showed downregulation 0.3, FGF2 also showed downregulation 0.4 and CARMA3 showed slight upregulation 1.2.
conclusionThe results suggest that miR-205, FGF2, and CARMA3 may serve as potential biomarkers for the identification of colorectal cancer (CRC), particularly when used in multi-marker panels to improve diagnostic accuracy. Their clinical utility should be confirmed through additional validation in larger cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.